Skip Nav Destination
Issues
Editorial
Minireview
The Biology Behind
Advances in Brief
Clinical Trials
Reduction of Wound Angiogenesis in Patients Treated with BMS-275291, a Broad Spectrum Matrix Metalloproteinase Inhibitor1
A. Craig Lockhart; Rod D. Braun; Daohai Yu; Joel R. Ross; Mark W. Dewhirst; Jeffrey S. Humphrey; Seth Thompson; Kathleen M. Williams; Bruce Klitzman; Fan Yuan; James M. Grichnik; Alan D. Proia; Delina A. Conway; Herbert I. Hurwitz
Clinical Trial
Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer1
Monica Santimaria; Giovanni Moscatelli; Giuseppe L. Viale; Leonardo Giovannoni; Giovanni Neri; Francesca Viti; Alessandra Leprini; Laura Borsi; Patrizia Castellani; Luciano Zardi; Dario Neri; Pietro Riva
Molecular Oncology, Markers, Clinical Correlates
High and Differential Expression of HER-2/neu Extracellular Domain in Bilateral Ductal Fluids from Women with Unilateral Invasive Breast Cancer1
Henry M. Kuerer; Patricia A. Thompson; Savitri Krishnamurthy; Herbert A. Fritsche; Sylvie M. Marcy; Gildy V. Babiera; S. Eva Singletary; Massimo Cristofanilli; Nour Sneige; Kelly K. Hunt
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients1
Carlo Gambacorti-Passerini; Massimo Zucchetti; Domenico Russo; Roberta Frapolli; Magda Verga; Silvia Bungaro; Lucia Tornaghi; Fabio Rossi; Pietro Pioltelli; Enrico Pogliani; Daniele Alberti; Gianmarco Corneo; Maurizio D’Incalci
Phase I Evaluation of Prolonged-infusion Gemcitabine with Fludarabine for Relapsed or Refractory Acute Myelogenous Leukemia1
David A. Rizzieri; Valerie K. Ibom; Joseph O. Moore; Carlos M. DeCastro; Gary L. Rosner; David J. Adams; Traci Foster; Nancy Payne; Maria Thompson; James J. Vredenburgh; Christina Gasparetto; Gwynn D. Long; Nelson J. Chao; Jon P. Gockerman
Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-11
Maha Ayyoub; Alfred Zippelius; Mikaël J. Pittet; Donata Rimoldi; Danila Valmori; Jean-Charles Cerottini; Pedro Romero; Ferdy Lejeune; Danielle Liénard; Daniel E. Speiser
Mechanisms of Peritoneal Metastasis after Operation for Non-Serosa-invasive Gastric Carcinoma: An Ultrarapid Detection System for Intraperitoneal Free Cancer Cells and a Prophylactic Strategy for Peritoneal Metastasis
Takashi Marutsuka; Shinya Shimada; Kenji Shiomori; Naoko Hayashi; Yasushi Yagi; Takaaki Yamane; Michio Ogawa
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study1
Laura G. Estévez; José Miguel Cuevas; Antonio Antón; Jesús Florián; José Manuel López-Vega; Amalia Velasco; Francisco Lobo; Ana Herrero; José Fortes
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-based Chemotherapy for Metastatic Colorectal Cancer
Wataru Ichikawa; Hiroyuki Uetake; Yoshinori Shirota; Hiroyuki Yamada; Naoto Nishi; Zenro Nihei; Kenichi Sugihara; Renzo Hirayama
Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy
Matthew H. T. Bui; David Seligson; Ken-ryu Han; Allan J. Pantuck; Frederick J. Dorey; Yunda Huang; Steve Horvath; Bradley C. Leibovich; Shefali Chopra; Shu-Yuan Liao; Eric Stanbridge; Michael I. Lerman; Aarno Palotie; Robert A. Figlin; Arie S. Belldegrun
Real-Time Analysis of Tyrosine Hydroxylase Gene Expression: A Sensitive and Semiquantitative Marker for Minimal Residual Disease Detection of Neuroblastoma1
Lambert H. J. Lambooy; Corrie E. M. Gidding; Lambert P. van den Heuvel; Christina A. Hulsbergen-van de Kaa; Marjolijn Ligtenberg; Jos P. M. Bökkerink; Ronney A. De Abreu
RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response
Herman Burger; John A. Foekens; Maxime P. Look; Marion E. Meijer-van Gelder; Jan G. M. Klijn; Erik A. C. Wiemer; Gerrit Stoter; Kees Nooter
Sequence Alterations in the Reduced Folate Carrier Are Observed in Osteosarcoma Tumor Samples1
Rui Yang; Rebecca Sowers; BethAnne Mazza; John H. Healey; Andrew Huvos; Holcombe Grier; Mark Bernstein; G. Peter Beardsley; Mark D. Krailo; Meenakshi Devidas; Joseph R. Bertino; Paul A. Meyers; Richard Gorlick
Establishment and Characterization of Cancer Cell Cultures and Xenografts Derived from Primary or Metastatic Mullerian Cancers1
Claire F. Verschraegen; Wei Hu; Yu Du; John Mendoza; Janet Early; Michael Deavers; Ralph S. Freedman; Robert C. Bast, Jr.; Andrzej P. Kudelka; John J. Kavanagh; Beppino C. Giovanella
Experimental Therapeutics, Preclinical Pharmacology
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Giampaolo Tortora; Rosa Caputo; Vincenzo Damiano; Roberta Caputo; Teresa Troiani; Bianca Maria Veneziani; Sabino De Placido; Angelo Raffaele Bianco; Uwe Zangemeister-Wittke; Fortunato Ciardiello
Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma1
Carolyn J. Henry; Dudley L. McCaw; Susan E. Turnquist; Jeff W. Tyler; Lina Bravo; Sarah Sheafor; Rodney C. Straw; William S. Dernell; Bruce R. Madewell; Linda Jorgensen; Michael A. Scott; Mary Lynn Higginbotham; Ruthanne Chun
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.